^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PIN-A1

    i
    Other names: PIN-A1
    Company:
    Pin Therap
    Drug class:
    CK1α degrader
    almost3years
    Discovery of potent and selective CK1α molecular degrader with a favorable safety profile for acute myeloid leukemia and solid tumors (AACR 2023)
    Also, we found that the combination treatment of PIN-A1 with agent X had a substantial effect on several solid tumors driven by enhancing the stability and activity of p53. In summary, these results suggest that a CK1α MGD with its favorable safety profile has a potential to become an effective treatment option for advanced AML and solid tumors.
    Clinical
    |
    CRBN (Cereblon)
    |
    TP53 mutation • TP53 wild-type
    |
    PIN-A1